FDA Approves VALSARTAN — Amneal Pharmaceuticals of New York LLC

Amneal Pharmaceuticals LLC announced the approval of its generic valsartan application (ANDA204011) on January 11, 2016, which is expected to broaden availability of the hypertension treatment as quality concerns surrounding the previous market leader escalate. This regulatory clearance marks a significant step for the company to capitalize on rising demand resulting from the successful litigation and subsequent market exit of Daiichi Sankyo.